SALIX PHARM (SLXP) XIFAXAN GETS FDA APPROVAL. ROTH CAPITAL UPS ESTIMATES, TARGET
undefined undefined | S&P Marketscope SNPMarketScopeViewsNews2010-03-25 09:14:42.000SLXPSALIX PHARMACEUTICALS, LTD.Barney BrodieSALIX PHARM (SLXP) XIFAXAN GETS FDA APPROVAL. ROTH CAPITAL UPS ESTIMATES, TARGETAnalyst Scott Henry tells salesforce SLXP announced FDA approved Xifaxan 550mg tablets for reduction in risk of overt hepatic encephalopathy (HE). Notes most investors expected a positive result given recent positive panel. Says his sense is that many estimates still hover around $160M-$170M for '10 Xifaxan sales; product exited '09 at $125M run rate; ~60% price increase already takes numbers to $200M before a penny of HE sales or net HE stocking. Raises $0.06 '10 EPS estimate to $0.08, $1.00 '11 to $1.40. Raises target to $43. Keeps buy./B.Brodie|US;SLXP|55332|US|255511
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
